Pharmafile Logo
Pharmafocus logo
Advanced Search

hepatitis C

Showing 15 posts of 65 posts found.

sovaldi iamge

Sovaldi performs for Gilead

April 24, 2014
Sales and Marketing Gilead, HCV, Q1, hepatitis C, sovaldi

Gilead Sciences’ once-daily, oral hepatitis C treatment Sovaldi has returned better than expected figures in the first quarter of the …

News

Patient death halts BMS hep C trial

August 30, 2012
Sales and Marketing BMS, HCV, hepatitis C

Bristol-Myers Squibb has admitted that the death of a patient was behind its decision to stop development of a potential …

News

Bristol-Myers Squibb halts Hep C pill study

August 2, 2012
Research and Development, Sales and Marketing BMS, hepatitis C, pill, trial suspension

Bristol-Myers Squibb has halted a mid-stage trial of a new Hepatitis C drug due to major safety concerns. In a …

News

Gilead aims for hep C lead with Pharmasset acquisition

November 22, 2011
Research and Development Gilead, HCV, Pharmasset, Victrelis, hepatitis C

Gilead Sciences is to buy Pharmasset for $11 billion in a bid to become a leader in hepatitis C treatment.The …

News

Boehringer hails hepatitis C candidate

November 9, 2011
Sales and Marketing BI201335, Boehringer Ingelheim, HCV, Incivo, Victrelis, hepatitis C

Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients’ treatment time …

News
Roche

Roche buys US firm Anadys for $230 million

October 17, 2011
Research and Development, Sales and Marketing Roche, hepatitis C

Roche has acquired US firm Anadys for $230 million, bolstering its infectious drugs pipeline. California-based Anadys develops oral, small molecule …

News
Boehringer

Boehringer signs away HIV rights to focus on hep C

October 7, 2011
Research and Development Boehringer, Gilead, HIV, hepatitis C

Boehringer Ingelheim has signed a deal giving Gilead Sciences exclusive worldwide rights to a major part of its HIV portfolio. …

News

Merck and Roche extend Victrelis co-promotion deal to Europe

July 22, 2011
Sales and Marketing Merck & Co, Roche, Victrelis, hepatitis C

Merck & Co is ramping up efforts to push its new hepatitis C treatment Victrelis to the fore, signing a …

News
MSD's Victrelis (boceprevir)

Hep C drug Victrelis gains EU approval

July 20, 2011
Sales and Marketing Incivek, Victrelis, hepatitis C

Merck Sharp & Dohme’s Victrelis, one of two major new hepatitis C drugs, has gained final approval in Europe. Victrelis …

News
Victrelis

Hepatitis C rivals go head to head

July 19, 2011
Sales and Marketing Incivek, Incivo, Victrelis, boceprevir, hepatitis C, telaprevir

 The field of hepatitis C treatment has two new groundbreaking medicines to treat the condition.Merck’s Victrelis (boceprevir) and Johnson & …

Feature

J&J and Vertex’s hep C drug Incivek approved by FDA

May 24, 2011
Sales and Marketing FDA, Incivek, Johnson & Johnson, Vertex, hepatitis C, telaprevir

The FDA has approved Johnson & Johnson/Vertex’s new oral hepatitis C drug Incivek. Incivek (telaprevir), a protease inhibitor, is now …

News
Merck & Co's Victrelis (boceprevir)

Merck and Roche sign hepatitis C co-promotion deal

May 18, 2011
Medical Communications, Sales and Marketing Merck, Roche, hepatitis C

Merck & Co and Roche have signed an agreement that will see them co-promote each other’s hepatitis C drugs in …

News
Merck & Co's Victrelis (boceprevir)

Merck’s hepatitis drug Victrelis approved by FDA

May 16, 2011
Sales and Marketing Merck & Co, Victrelis, boceprevir, hepatitis C

The FDA has approved Merck’s hepatitis C drug Victrelis, the first oral treatment for the disease. Victrelis (boceprevir) has been …

News
Boehringer Ingelheim

Boehringer begins late-stage hep C trial

April 27, 2011
Research and Development BI 201335, Boehringer Ingelheim, hepatitis C

Boehringer Ingelheim has begun enrolling patients in North America for a phase III trial of its chronic hepatitis C virus …

News

New BMS drug trumps peg-interferon alpha

April 4, 2011
Research and Development, Sales and Marketing BMS, EASL, hepatitis C, pegintron alfa

Bristol-Myers Squibb has been given a boost by trial results which suggest its compound for hepatitis C, PEG-Interferon lambda, is …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026